KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non Operating Income (2017 - 2025)

Historic Non Operating Income for Teva Pharmaceutical Industries (TEVA) over the last 13 years, with Q4 2025 value amounting to -$220.0 million.

  • Teva Pharmaceutical Industries' Non Operating Income fell 91.74% to -$220.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$934.0 million, marking a year-over-year increase of 479.1%. This contributed to the annual value of -$934.0 million for FY2025, which is 479.1% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Non Operating Income stood at -$220.0 million, which was down 91.74% from -$237.0 million recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Non Operating Income peaked at -$211.0 million during Q2 2022, and registered a low of -$290.0 million during Q1 2021.
  • Moreover, its 5-year median value for Non Operating Income was -$251.0 million (2022), whereas its average is -$249.8 million.
  • In the last 5 years, Teva Pharmaceutical Industries' Non Operating Income tumbled by 10598.29% in 2021 and then skyrocketed by 2299.27% in 2022.
  • Teva Pharmaceutical Industries' Non Operating Income (Quarter) stood at -$253.0 million in 2021, then increased by 3.16% to -$245.0 million in 2022, then fell by 1.63% to -$249.0 million in 2023, then grew by 12.45% to -$218.0 million in 2024, then fell by 0.92% to -$220.0 million in 2025.
  • Its last three reported values are -$220.0 million in Q4 2025, -$237.0 million for Q3 2025, and -$252.0 million during Q2 2025.